Syringocystadenocarcinoma Papilliferum: A Case Report

Abstract

Syringocystadenocarcinoma papilliferum (SCACP) is a rare form of adenocarcinoma of the skin. This is the malignant counterpart of syringocystadenoma papilliferum (SCAP) and usually develops on the scalp in a long-standing lesion identified clinically as SCAP. We describe a 65-yr-old Korean man with a nodule on the right supra-pubic area with a 2-yr duration. Histologically this tumor had a similar overall configuration as in SCAP, but the tumor was asymmetric and poorly circumscribed, extending into the deep dermis and showed cytologic atypia. The tumor cells showed positive reaction to GCDFP-15, but negative reaction to CEA and HMFG-1. We established the diagnosis of SCACP in the patient, and a wide excision was performed to remove the tumor. The patient has been well without relapse or metastasis for 2 yr.

Syringocystadenocarcinoma papilliferum at unusual site: inherent lesional histologic polymorphism is the pathognomon

“…Cribriform, papillary intraductal, clinging and columnar cell patterns with focal apocrine like decapitation secretions observed, closely resembled the similarly named mammary counterparts figure 2 4 5…”

A Rare Tumor: Syringocystadenocarcinoma Papilliferum

“…SCACP is a malignant form of syringocystadenoma papilliferum (SCAP). 1 Occasionally, SCAP cases present as nodular or plaque-like lesions, but SCACP is rarely seen. 2 It may develop from SCAP lesions or nevus sebaceous of Jadassohn.…”

“…2 It may develop from SCAP lesions or nevus sebaceous of Jadassohn. 1 There have been 13 cases of SCACP reported in the literature. Here, we report and discuss the 14th case of SCACP occurring on the scalp of a 67-year-old man.…”

Syringocystadenocarcinoma papilliferum in situ originating from the perianal skin

“…SCACP is considered to represent the malignant counterpart of SCAP, with <10 cases having been reported so far. Most of the lesions, in fact, seem to have arisen from long‐standing SCAP (3). In 2003, Arai et al (1) reported a case of SCACP in situ , separating their lesion from conventional SCAP by the presence of a disorderly arrangement of multilayered cells with atypical nuclei.…”